CV Sciences, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
CV Sciences, Inc. (CVSI) reported Net Income (Loss) Available to Common Stockholders, Diluted of $3.10 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-03-29
- CV Sciences, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-12-31 was -$869.00K.
- CV Sciences, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was -$447.00K.
- CV Sciences, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-06-30 was -$1.29M.
- CV Sciences, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-03-31 was $5.71M.
- CV Sciences, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was $3.10M.
- CV Sciences, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$9.13M.
- CV Sciences, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$15.55M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$869.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$1.32M derived: sum of 2 quarters · filed 2024-03-29 | -$2.60M derived: sum of 3 quarters · filed 2024-03-29 | $3.10M 10-K · filed 2024-03-29 |
| 2023-09-30 | -$447.00K 10-Q · filed 2023-11-14 | -$1.74M derived: sum of 2 quarters · filed 2023-11-14 | $3.97M 10-Q · filed 2023-11-14 | $1.66M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-06-30 | -$1.29M 10-Q · filed 2023-08-14 | $4.42M 10-Q · filed 2023-08-14 | $2.10M derived: sum of 3 quarters · filed 2024-03-29 | $1.07M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-03-31 | $5.71M derived: 10-K 12 month − 3 quarters · filed 2024-03-29 | $3.39M derived: sum of 2 quarters · filed 2024-03-29 | $2.36M derived: sum of 3 quarters · filed 2024-03-29 | -$1.21M derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | -$2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$3.34M derived: sum of 2 quarters · filed 2024-03-29 | -$6.92M derived: sum of 3 quarters · filed 2024-03-29 | -$9.13M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$1.03M 10-Q · filed 2023-11-14 | -$4.60M derived: sum of 2 quarters · filed 2023-11-14 | -$6.82M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$3.57M 10-Q · filed 2023-08-14 | -$5.79M 10-Q · filed 2023-08-14 | ||
| 2021-12-31 | -$8.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$8.90M derived: sum of 2 quarters · filed 2023-03-30 | -$12.43M derived: sum of 3 quarters · filed 2023-03-30 | -$15.55M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$40.00K 10-Q · filed 2022-11-14 | -$3.57M derived: sum of 2 quarters · filed 2022-11-14 | -$6.70M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$3.53M 10-Q · filed 2022-08-15 | -$6.66M 10-Q · filed 2022-08-15 |